Edgestream Partners L.P. Sells 19,845 Shares of Merck & Co., Inc. $MRK

Key Points

• Edgestream Partners L.P. cut its Merck stake by 86.2% in the first quarter, selling 19,845 shares and retaining 3,181 shares valued at approximately $383,000. Institutional investors collectively own 76.07% of Merck.
• Merck’s latest quarter exceeded expectations, with revenue of $16.61 billion and an adjusted loss of $0.13 per share; revenue increased 5.1% year over year, driven largely by Keytruda. The company raised its 2026 revenue outlook but lowered EPS guidance to $2.66-$2.76, partly due to acquisition-related charges.
• Merck declared a quarterly dividend of $0.85 per share, equivalent to a 2.6% annual yield. Analysts remain broadly positive, with a “Moderate Buy” consensus and an average price target of $134.56, though investors remain focused on Keytruda’s expected 2028 patent expiration.

Edgestream Partners L.P. lowered its holdings in shares of Merck & Co., Inc. (NYSE:MRK - Free Report) by 86.2% during the first quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 3,181 shares of the company's stock after selling 19,845 shares during the period. Edgestream Partners L.P.'s holdings in Merck & Co., Inc. were worth $383,000 as of its most recent SEC filing.

Other institutional investors and hedge funds have also recently bought and sold shares of the company. Kingdom Financial Group LLC. bought a new position in shares of Merck & Co., Inc. during the 4th quarter worth about $25,000. Abound Financial LLC bought a new stake in Merck & Co., Inc. in the fourth quarter valued at about $26,000. Prosperity Bancshares Inc bought a new stake in Merck & Co., Inc. in the fourth quarter valued at about $26,000. High Note Wealth LLC raised its position in Merck & Co., Inc. by 58.9% in the fourth quarter. High Note Wealth LLC now owns 294 shares of the company's stock worth $31,000 after purchasing an additional 109 shares in the last quarter. Finally, IFC & Insurance Marketing Inc. acquired a new position in Merck & Co., Inc. in the fourth quarter worth about $31,000. Institutional investors own 76.07% of the company's stock.

Merck & Co., Inc. Stock Up 0.3%

Shares of MRK opened at $128.33 on Thursday. The company has a market capitalization of $316.95 billion, a P/E ratio of 102.66, a PEG ratio of 5.13 and a beta of 0.19. Merck & Co., Inc. has a one year low of $77.58 and a one year high of $135.05. The business's 50 day simple moving average is $123.61 and its 200-day simple moving average is $118.91. The company has a debt-to-equity ratio of 1.02, a current ratio of 1.30 and a quick ratio of 1.06.

Merck & Co., Inc. (NYSE:MRK - Get Free Report) last released its quarterly earnings results on Tuesday, August 4th. The company reported ($0.13) earnings per share for the quarter, beating analysts' consensus estimates of ($0.26) by $0.13. The firm had revenue of $16.61 billion during the quarter, compared to analysts' expectations of $16.37 billion. Merck & Co., Inc. had a return on equity of 16.05% and a net margin of 4.77%.The business's revenue was up 5.1% on a year-over-year basis. During the same period last year, the firm posted $2.13 EPS. Merck & Co., Inc. has set its FY 2026 guidance at 2.660-2.760 EPS. As a group, sell-side analysts predict that Merck & Co., Inc. will post 2.72 EPS for the current fiscal year.

Merck & Co., Inc. Dividend Announcement

The business also recently declared a quarterly dividend, which will be paid on Wednesday, October 7th. Investors of record on Tuesday, September 15th will be given a dividend of $0.85 per share. The ex-dividend date is Tuesday, September 15th. This represents a $3.40 annualized dividend and a yield of 2.6%. Merck & Co., Inc.'s dividend payout ratio is 272.00%.

Analysts Set New Price Targets

A number of research firms have weighed in on MRK. Bank of America lifted their price objective on Merck & Co., Inc. from $130.00 to $141.00 and gave the company a "buy" rating in a report on Tuesday, June 30th. Cantor Fitzgerald reissued a "neutral" rating and issued a $120.00 target price on shares of Merck & Co., Inc. in a report on Monday, July 6th. UBS Group raised their target price on Merck & Co., Inc. from $130.00 to $145.00 and gave the stock a "buy" rating in a research report on Monday, April 13th. Wall Street Zen downgraded Merck & Co., Inc. from a "buy" rating to a "hold" rating in a research report on Monday, July 20th. Finally, Barclays boosted their price target on Merck & Co., Inc. from $140.00 to $150.00 and gave the company an "overweight" rating in a research note on Wednesday, July 29th. Thirteen investment analysts have rated the stock with a Buy rating and seven have given a Hold rating to the stock. According to MarketBeat, the company presently has a consensus rating of "Moderate Buy" and an average price target of $134.56.

Trending Headlines about Merck & Co., Inc.

Here are the key news stories impacting Merck & Co., Inc. this week:

• Positive Sentiment: Merck reported second-quarter revenue of $16.61 billion, above the $16.37 billion consensus estimate, while its adjusted loss of $0.13 per share was narrower than the expected $0.26 loss. Revenue grew 5.1% year over year. Merck posts better-than-expected second-quarter results on Keytruda strength
• Positive Sentiment: Keytruda remained the primary growth driver, generating $8.37 billion in quarterly sales, while the injectable formulation substantially exceeded Wall Street expectations. Newer products and pipeline programs also supported the company’s performance. The Merck Product That Absolutely Demolished Wall Street's Forecasts
• Positive Sentiment: Merck raised its 2026 revenue outlook to $66.3 billion-$67.3 billion, reflecting confidence in Keytruda, newer launches and pipeline progress. Guggenheim also raised its price target to $146 and maintained a Buy rating. MRK Q2 Earnings & Sales Beat Estimates, '26 Sales View Raised
• Positive Sentiment: Health Canada approved Keytruda combined with enfortumab vedotin for certain cisplatin-ineligible patients with muscle-invasive bladder cancer, expanding the drug’s commercial reach. Health Canada approves Keytruda treatment
• Neutral Sentiment: Merck is accelerating acquisitions and partnerships in hematology, infectious diseases, vaccines, cardiopulmonary medicine and obesity to diversify ahead of Keytruda’s expected U.S. patent-exclusivity loss in 2028. The strategy offers long-term upside but increases execution and spending risks. Merck is racing beyond Keytruda
• Negative Sentiment: Merck lowered its 2026 EPS guidance to $2.66-$2.76, well below the $3.42 consensus, primarily because of acquisition-related charges tied to Terns Pharmaceuticals and other deals. Merck hikes revenue outlook but cuts profit guidance
• Negative Sentiment: Investors remain concerned that Keytruda’s 2028 patent cliff could create a significant revenue gap unless newer products, acquisitions and clinical programs deliver sufficient replacement growth. Merck also reported a mixed development update for anti-TL1A drug tulisokibart, which was discontinued in one rare lung-disease indication. MSD posts a victory and defeat for anti-TL1A

About Merck & Co., Inc.

Merck & Co, Inc is a global biopharmaceutical company engaged in the discovery, development, manufacture and marketing of prescription medicines, vaccines, biologic therapies and animal health products. Its portfolio spans multiple therapeutic areas with a particular emphasis on oncology, vaccines and infectious disease, as well as therapies for metabolic and chronic conditions. Among its well-known products are the cancer immunotherapy Keytruda (pembrolizumab) and the human papillomavirus vaccine Gardasil; the company also markets a range of medicines and vaccines for veterinary use through Merck Animal Health.

Founded in the late 19th century as the U.S.

Want to see what other hedge funds are holding MRK? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Merck & Co., Inc. (NYSE:MRK - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source